"Selinexor+Pegaspargase+Dexamethasonein Ⅰ/Ⅱ NKTCL"

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

September 1, 2024

Primary Completion Date

December 1, 2026

Study Completion Date

December 31, 2026

Conditions
NKTCLSelinexor
Interventions
DRUG

Selinexor+pegaspargase+dexamethasone

Nuclear export protein-1 is the main transporter protein for leucine-rich proteins to enter the cytoplasm from the nucleus through the nuclear pore complex, which is overexpressed in malignant tumor cells. Studies have shown that Selinexor inhibits the nuclear export of viral mRNA such as EBV, and has good therapeutic potential for NKTCL. Selinexor combined with pemaspartase, dexamethasone and sequential radiotherapy may be the golden choice for early NK/T cell lymphoma, improving the local control rate of the disease and improving the overall prognosis of NK/T cell lymphoma.

Trial Locations (1)

450052

RECRUITING

Oncology Department of The First Affilliated Hospital of Zhengzhou University, Zhengzhou

All Listed Sponsors
lead

Mingzhi Zhang

OTHER